Carboplatin: a clinical review.

Area of Science:

• Oncology
• Pharmacology
• Medical Chemistry

Background:

• Carboplatin is a platinum-based chemotherapy drug.
• It is an analog of cisplatin, a widely used chemotherapy agent.
• Carboplatin was developed to offer a better safety profile compared to cisplatin.

Purpose of the Study:

• To evaluate the efficacy and toxicity of carboplatin.
• To compare carboplatin with cisplatin in terms of clinical outcomes and patient quality of life.
• To explore potential applications of carboplatin in specific cancer types and patient populations.

Main Methods:

• Preclinical studies and clinical trials were reviewed.
• Pharmacological properties, including nephrotoxicity, neurotoxicity, and emetic potential, were assessed.
• Antitumor activity spectrum was compared to cisplatin.
• Dose-limiting toxicities were identified.
• Potential use in autologous bone marrow transplantation (ABMT) for refractory germ cell cancers and in patients with renal impairment was investigated.

Main Results:

• Carboplatin exhibits a similar spectrum of antitumor activity to cisplatin.
• Carboplatin demonstrates reduced nephrotoxicity, neurotoxicity, and emetic effects compared to cisplatin.
• Myelotoxicity is the dose-limiting toxicity for carboplatin.
• Carboplatin offers advantages in patient quality of life.
• It shows promise in combination regimens for refractory germ cell cancers and as an alternative for patients with compromised renal function.

Conclusions:

• Carboplatin is a valuable chemotherapeutic agent with a favorable toxicity profile compared to cisplatin.
• Its efficacy in various cancers, coupled with improved tolerability, makes it a significant alternative.
• Carboplatin represents an important option for specific patient groups, including those with renal insufficiency and certain refractory malignancies.